NCT06526000View on ClinicalTrials.gov

Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies

CompletedOBSERVATIONAL
Enrollment

326

Participants

Timeline

Start Date

October 11, 2022

Primary Completion Date

February 28, 2024

Study Completion Date

February 28, 2024

Conditions
Relapsing Multiple SclerosisClinically Isolated SyndromeRelapsing-remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
Trial Locations (1)

07936

Novartis Pharmaceuticals, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY